Get the Stockscreener App
46.38
1.90%
-0.90
After Hours:
46.38
Biohaven Ltd stock is traded at $46.38, with a volume of 554.49K.
It is down -1.90% in the last 24 hours and down -12.23% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$47.28
Open:
$47.1
24h Volume:
554.49K
Relative Volume:
0.56
Market Cap:
$4.74B
Revenue:
-
Net Income/Loss:
$-746.61M
P/E Ratio:
-6.2088
EPS:
-7.47
Net Cash Flow:
$-485.24M
1W Performance:
-0.96%
1M Performance:
-12.23%
6M Performance:
+26.31%
1Y Performance:
+47.52%
1-Day Range:
$46.17
$47.75
1-Week Range:
$40.80
$47.75
52-Week Range:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
46.38 | 4.74B | 0 | -746.61M | -485.24M | -7.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven’s Phase III SMA miss: was it the target or the trial design? - BioCentury
Biohaven's (BHVN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Scholar Rock shares surge 26% as rival Biohaven misses SMA study goal - TradingPedia
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial - BioPharma-Reporter.com
Biohaven's spinal muscular atrophy drug fails to meet study goal - Reuters
Biohaven shares retains overweight rating on clinical trial By Investing.com - Investing.com South Africa
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Yahoo Finance
Biohaven muscle drug misses goal of SMA study, but advances in obesity - BioPharma Dive
Biohaven down 5% as spinal muscular atrophy asset misses primary endpoint - Seeking Alpha
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire
GSA Capital Partners LLP Has $230,000 Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Proposed Public Offering of Common Shares - GuruFocus.com
Biohaven's SWOT analysis: stock poised for potential growth amid clinical trials - Investing.com Nigeria
Biohaven Announces Pricing of $250 Million Public Offering of Co - GuruFocus.com
Biohaven's SWOT analysis: stock poised for potential growth amid clinical trials By Investing.com - Investing.com South Africa
When (BHVN) Moves Investors should Listen - Stock Traders Daily
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biohaven Ltd. (NYSE:BHVN) Shares Sold by First Turn Management LLC - MarketBeat
Victory Capital Management Inc. Buys 145,960 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven (NYSE:BHVN) Stock Price Down 8%Should You Sell? - MarketBeat
Janus Henderson Group PLC's Strategic Acquisition of Biohaven Lt - GuruFocus.com
Biohaven's (BHVN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - The Malaysian Reserve
Biohaven shares rise as TD Cowen lifts price target to $75 - Investing.com Australia
Royal Bank of Canada Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat
12,400 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by SpiderRock Advisors LLC - MarketBeat
Trend Tracker for (BHVN) - Stock Traders Daily
Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $61.92 - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
(BHVN) Technical Data - Stock Traders Daily
Biohaven's (BHVN) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
(BHVN) Trading Advice - Stock Traders Daily
Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK
Analysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $61.92 - MarketBeat
Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat
(BHVN) Investment Analysis - Stock Traders Daily
17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat
Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa
Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India
Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia
Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat
Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St
Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):